Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Stem CentRx
- 24 Apr 2017 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Results published in the Lancet Oncology
- 01 Nov 2016 Results published in the Journal of Thoracic Oncology